23 Apr 2015
Author(s): 
Corporate author: The RTS,S Clinical Trials Partnership

Please note that you will need to register and login to access the full article for free on TheLancet.com.

The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of follow-up have been published previously. Herein, we report the final results from the same trial, including the efficacy of a booster dose.